Spring is finally here, which means it's time to break out the broom and dustpan for some spring cleaning.

But your home isn't the only thing that requires constant maintenance -- your portfolio does too.

And what better time than spring to get a fresh start by cleaning out the stocks that are sitting around collecting dust rather than making you money?

"It's time for income investors to come back to what's historically been a mainstay of diversified portfolios: big pharmaceutical companies. We're adding one of the sector's most durable members to the Income Portfolio, Bristol-Myers Squibb (BMY)," says Roger Conrad.

In Personal Finance newsletter, he explains, "The stock has been a lackluster performer since the 1990s, when it was last a Portfolio recommendation. The company's underlying business, however, has become ever-more valuable.

"Stocks are likely in a new downtrend," says Michael Ashbaugh. In Marketwatch's The Technical Indicator, he looks at the S&P's prospects and some drug stocks set to buck the trend.

"The S&P 500 has violated its major moving averages in the closely tracked 900 area. The recent downturn was convincingly bearish, placing the burden on market bulls to reassert the uptrend.

"After finding resistance in the 923 area, the S&P sold off sharply, edging back under its 200-day moving average, which currently holds at 900 and now marks resistance. This is bearish price action.

"Few industries seem as well positioned for future growth as the generic drug industry," says small-cap growth stock specialist Tom Bishop.

In his BI Research newsletter, he explains, "With demographic pointing to an increasingly aging population, and healthcare costs spiraling out of control, low cost generic drugs are clearly part of the solution." Here's a look at generic drug maker Mylan (NYSE: MYL).

"High on the agenda of the Obama administration is to bring health care coverage to some 40 million Americans who are currently not covered.

In a review of the pharmaceutical sector, Chuck Carlson selects his favorite International stocks which also offer direct-purchase plans for U.S. investors.

Here's a look at two of these stocks -- United Kingdom-based AstraZeneca (NYSE: AZN) and Denmark-based Novo Nordisk (NYSE: NVO) -- from his The DRIP Investor, a newsletter focused on long-term, high quality investments.

"AstraZeneca is a leading pharmaceutical firm. The company boasts a portfolio that includes 11 products that generate more than $1 billion each in annual sales.

This post is part of a 12-article feature on the best bets for investing in China. To see all the other recommendations in this special report, click here.

"Shanghai-based Wuxi PharmaTech (NYSE: WX), a new addition to our model portfolio, is a bargain," says China region expert Jim Trippon.

In his The China Stock Digest, he explains, "In a nutshell, WuXi performs pharmaceutical R&D on a contract basis for paying clients; it provides services to nine of the top ten pharmaceutical companies in the world."

"Wall Street has been nonplussed about results from Bristol-Myers Squibb (NYSE: BMY); in my view, the Street is wrong," says Karim Rahemtulla in Xcelerated Profits Report.

"The stock has not joined many of its colleagues on the upside recently, but you can take Wall Street's lackluster opinion with a grain of salt. Yes, BMY's revenue of $5.02 billion fell a bit shy of projections for $5.13 billion, mostly due to a strong dollar negatively impacting sales.

"But sales grew 2.5% over the same period a year ago and earnings of 48 cents per share beat estimates by a penny. And with sales of Plavix rising 10% and demand for anti-depressant Abilify jumping 30%, it's hardly bad news.

"Abbott Laboratories (NYSE: ABT) is continuing its long record of rewarding shareholders," notes Alex Kolb In Zacks Elite, pointing to its 341st consecutive quarter of dividends since 1924.

"Abbott is a global, broad-based health care company that develops, manufactures and markets pharmaceuticals and medical products, including nutritionals, devices and diagnostics.

"The company employs more than 68,000 people and markets its products in more than 130 countries.

"The company recently released new data, showing that a combination of its new TriLipix triglycerides medicine and a low dose of AstraZeneca's Crestor cholesterol drug are better than the individual pills for treating heart problems.

"After warning that it would only achieve the low end of its previous guidance range for 2009, Celgene (NASDAQ: CELG) sold off significantly," notes biotech expert John McCamant.

Nevertheless, in his The Medical Technology Stock Letter he sees the selloff as any opportunity, calling the company a "great growth story."

"Celgene pre-announced 1Q 09 revenues of $600 million, which was significantly below Wall Street consensus estimates of $640-$650 million.

"The earnings miss was completely unexpected, and has partially shaken the belief that the Big Bios would be able to deliver solid earnings despite the economic problems.Nevertheless, we remain positive on the CELG story.

"Is Bristol-Myers Squibb (NYSE: BMY) ripe for a buyout?," asks growth expert Karim Rahemtulla. Here's an assessment from the investment director of Xcelerated Profits Report.

"I've predicted over the last several months that the larger pharmaceutical companies would be on the prowl for possible acquisitions.

"As it stands now, we probably haven't seen the last of such offers - and thanks to the previous two large mergers recently announced Merck acquiring Schering Plough and Pfizer buying Wyeth, many analysts are now speculating that Bristol-Myers Squibb could be next.

This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

"Johnson & Johnson (NYSE: JNJ) is an a typically defensive industry and has held up much better than most stocks during the past year," says John Reese, who selects the issue has his favorite stock for 2009.

In his Validea -- a newsletter that screens stocks based on the criteria used by legendary investors -- he assesses Johnson & Johnson based on his Warren Buffett and Peter Lynch models.

"The health care and pharmaceutical giant has dipped about 10% over the past year compared to the broader market's 40% plunge.

"In addition, the company has the size ($163 billion market cap) and breadth (250 operating companies and big brand names like Tylenol, Band-Aid, and Neutrogena) to withstand continuing trouble in the economy.

"Johnson & Johnson's price dip this year has only made it more of a bargain according to two of my Guru Strategy computer models, each of which is based on the approach of a different Wall Street great.

This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

"My selection for 2009 is Bristol-Myers Squibb (NYSE: BMY)," says Chuck Carlson, the leading advisor in the area of dividend reinvestment plans.

In his The DRIP Investor, he explains, "This pharmaceutical company has a lot to offer investors, including a high yield, a rising profit stream, and a speculative kicker in the way of takeover appeal." Here's his review.

"Bristol-Myers Squibb has a number of popular brands, including Plavix, the company's leading cardiovascular product; HIV treatments Reyataz and Sustiva; and oncology product Erbitux. Its stable of products has helped drive decent sales growth.

"Bristol-Myers Squibb has done a nice job of ?rming up its balance sheet. The company's cash coffers were boosted by the sale of its ConvaTec medical-device and wound-care business for $4.1 billion.

"At the end of the third quarter, the ?rm had more than $7 billion in cash and securities, a 'signi?cant majority' of which was invested in Treasury Bills and Treasury-backed securities.

This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

"My top idea for 2009 is Myriad Genetics (NASDAQ: MYGN)," says Mike Cintolo. In The Cabot Market Letter, he looks at "the leader in the new field of cancer predisposition testing."

"Myriad Genetics five tests on the market (covering colon, breast, ovarian, and skin cancer) that tell a patient if his genes make it more likely that he'll get various types of cancer.

"During the past few quarters, revenues from these tests have risen at a 50% annual clip, and there's no sign of that slowing down.

"The company also has a pharmaceutical division, but it's going to spin that off sometime in 2009. That should be a big positive, as the drug development division carries good potential, but also big-time costs. Once the cancer predisposition testing division is on its own, much of that revenue growth is going to fall to the bottom line.

This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

"We're not bullish on stocks until we see an improving economy; but if I had to choose a top pick for 2009, I have no problems choosing Pfizer (NYSE: PFE)," says Alan Newman in CrossCurrents.

"Given a lousy environment for stocks in the last half of 2008 and what appears to be the same going forward for the year ahead, the only logical course is to choose a company that pays a generous dividend.

"That will reward us for whatever patience will be required for our investment holding period. Thus, Pfizer, with its hefty 7.5% yield, makes good sense.

"In a bear market such as now, there are always minuses to consider. Pfizer has recently announced that, for the first time in 40 years, they are not raising their dividend.

"As well, Lipitor is the company's most successful product and it will lose patent protection just a couple of years down the road. Furthermore, there does not seem to be any blockbusters in the pipeline to replace Lipitor's $13 billion in sales.